Umoja Biopharma Announces Oral and Poster Presentations at the 66th American Society of Hematology Annual Meeting
November 05, 2024 09:05 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
October 04, 2024 09:05 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
September 30, 2024 16:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit
September 11, 2024 16:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
July 31, 2024 07:00 ET
|
Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
June 13, 2024 08:00 ET
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Toxicology Drug Testing Market Revenue to Cross USD 55.9 billion by 2031, Growing at a CAGR of 5.5% Says Transparency Market Research
August 28, 2023 04:17 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global toxicology drug testing market is projected to flourish at a CAGR of 5.5% from...
Inotiv, Inc. Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato BioPharma, Inc.
October 04, 2021 16:05 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN
March 09, 2021 08:33 ET
|
Bioanalytical Systems, Inc.
WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of...
I.M. (Gina) Grossi, Ph.D., Joins Inotiv as Vice President of Toxicology to Drive Growth of Expanding Toxicology Business
August 11, 2020 08:33 ET
|
Bioanalytical Systems, Inc.
WEST LAFAYETTE, Ind., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“Inotiv”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of...